New heteroleptic complexes (1–8) containing Zn(II) ion coordinated to an N,N-chelating ligand (the 4,4′-dinonyl-2,2′-bipyridine, bpy-9) and to diketonates L such as tropoloids (Tropolone and Hinokitiol) or 1-phenyl-3-methyl-4-R-5-pyrazolones have been synthesized by using different stoichiometric ratio with respect to the L ancillary ligand. The molecular structure of the bis-tropolonate derivative [(bpy-9)Zn(L)2] 5 has been determined by single-crystal X-ray diffraction. The antitumour activity of all Zn(II) complexes was tested in vitro against three different human prostate cancer cells: DU145, LNCaP and PC-3. Moreover, their effect on cell survival signalling and/or inhibitors of the PC-3 cell cycle have been analyzed. The results indicate that 1–8 exhibit strong cytotoxic activity against all cell lines affecting key molecules such as p-AKT and p21 waf, involved in the cell proliferation and/or arrest. Zinc(II) is thus a promising alternative to Pt(II) ion in the design of new, better performing antitumour agents.
新合成的异配合物(1–8),包含与N,N-螯合
配体(4,4′-二诺尼尔-2,2′-双
吡啶,bpy-9)和二
酮酸盐L配位的Zn(II)离子,这些二
酮酸盐包括类热带醌(热带醌和
檀香醇)或1-苯基-3-甲基-4-R-5-
吡唑酮,通过使用不同的配比与L辅助
配体合成。双热带酸酯衍
生物[(bpy-9)Zn(L)2] 5的分子结构通过单晶X射线衍射确定。所有Zn(II)配合物的抗肿瘤活性在体外针对三种不同的人前列腺癌细胞进行了测试:DU145、LNCaP和PC-3。此外,还分析了它们对细胞存活信号和/或PC-3细胞周期
抑制剂的影响。结果表明,1–8对所有
细胞系表现出强的细胞毒性活性,影响关键分子如p-AKT和p21 waf,这些分子参与细胞增殖和/或停滞。因此,
锌(II)成为设计新型、更有效抗肿瘤剂的有前景的替代选择。